Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)

Josephine L. Feliciano, Jennifer Le-Rademacher, Ajeet Gajra, Martin J. Edelman, Tyler Zemla, Ryan McMurray, Hongbin Chen, Arti Hurria, Hyman Muss, Harvey J. Cohen, Rogerio Lilenbaum, Aminah Jatoi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: This study sought to define the role of first-line platinum-based doublet chemotherapy in older patients with non-small cell lung cancer (NSCLC). Materials and Methods: We analyzed three first-line NSCLC trials: CALGB 9730, CALGB 30203, and CALGB 30801, which tested carboplatin and paclitaxel; carboplatin and gemcitabine; and carboplatin with either pemetrexed or gemcitabine, respectively. Overall survival was the primary endpoint. Age-based comparisons with a cutpoint of 65 years were performed with Cox proportional hazards models with adjustments for sex, tumor histology, cancer stage, chemotherapy, and smoking history and after stratifying by performance score. Secondary endpoints were grade 3–5 adverse events, chemotherapy cycles completed, and whether toxicity prompted chemotherapy discontinuation. Results: 730 patients were included; 337 (46%) were 65+ years of age. No statistically significant difference in survival was observed for older (≥65) versus younger patients (HR = 1.096; 95% CI = (0.94, 1.28); p = 0.25). A trend emerged with increased odds of a grade 3–5 adverse event for patients ≥65 years versus <65 years (OR = 1.52; 95% CI = (0.99, 2.31); p = 0.05). The proportion of completed chemotherapy cycles was marginally lower in older patients (difference = −5%; 95% CI = (−9, 0.2); p = 0.06) for those ≥65 years versus <65 years, but no statistically significant difference occurred in the rate of chemotherapy discontinuation for toxicity (OR = 1.4; 95% CI = (0.85, 2.19); p = 0.21) for patients ≥65 years versus <65 years. A cutpoint of 70 years yielded similar results. Conclusion: These findings support carboplatin doublet-based chemotherapy in select older patients with advanced NSCLC.

Original languageEnglish (US)
JournalJournal of Geriatric Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Carboplatin
Drug Therapy
gemcitabine
Pemetrexed
Survival
Paclitaxel
Proportional Hazards Models
Neoplasms
Histology
Smoking
History

Keywords

  • Carboplatin
  • Chemotherapy
  • Geriatric oncology
  • Lung cancer
  • Older patients

ASJC Scopus subject areas

  • Oncology
  • Geriatrics and Gerontology

Cite this

Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). / Feliciano, Josephine L.; Le-Rademacher, Jennifer; Gajra, Ajeet; Edelman, Martin J.; Zemla, Tyler; McMurray, Ryan; Chen, Hongbin; Hurria, Arti; Muss, Hyman; Cohen, Harvey J.; Lilenbaum, Rogerio; Jatoi, Aminah.

In: Journal of Geriatric Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Feliciano, Josephine L. ; Le-Rademacher, Jennifer ; Gajra, Ajeet ; Edelman, Martin J. ; Zemla, Tyler ; McMurray, Ryan ; Chen, Hongbin ; Hurria, Arti ; Muss, Hyman ; Cohen, Harvey J. ; Lilenbaum, Rogerio ; Jatoi, Aminah. / Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). In: Journal of Geriatric Oncology. 2018.
@article{c39b3f941a8d42798b1ed2d8c0ee3dbd,
title = "Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)",
abstract = "Objective: This study sought to define the role of first-line platinum-based doublet chemotherapy in older patients with non-small cell lung cancer (NSCLC). Materials and Methods: We analyzed three first-line NSCLC trials: CALGB 9730, CALGB 30203, and CALGB 30801, which tested carboplatin and paclitaxel; carboplatin and gemcitabine; and carboplatin with either pemetrexed or gemcitabine, respectively. Overall survival was the primary endpoint. Age-based comparisons with a cutpoint of 65 years were performed with Cox proportional hazards models with adjustments for sex, tumor histology, cancer stage, chemotherapy, and smoking history and after stratifying by performance score. Secondary endpoints were grade 3–5 adverse events, chemotherapy cycles completed, and whether toxicity prompted chemotherapy discontinuation. Results: 730 patients were included; 337 (46{\%}) were 65+ years of age. No statistically significant difference in survival was observed for older (≥65) versus younger patients (HR = 1.096; 95{\%} CI = (0.94, 1.28); p = 0.25). A trend emerged with increased odds of a grade 3–5 adverse event for patients ≥65 years versus <65 years (OR = 1.52; 95{\%} CI = (0.99, 2.31); p = 0.05). The proportion of completed chemotherapy cycles was marginally lower in older patients (difference = −5{\%}; 95{\%} CI = (−9, 0.2); p = 0.06) for those ≥65 years versus <65 years, but no statistically significant difference occurred in the rate of chemotherapy discontinuation for toxicity (OR = 1.4; 95{\%} CI = (0.85, 2.19); p = 0.21) for patients ≥65 years versus <65 years. A cutpoint of 70 years yielded similar results. Conclusion: These findings support carboplatin doublet-based chemotherapy in select older patients with advanced NSCLC.",
keywords = "Carboplatin, Chemotherapy, Geriatric oncology, Lung cancer, Older patients",
author = "Feliciano, {Josephine L.} and Jennifer Le-Rademacher and Ajeet Gajra and Edelman, {Martin J.} and Tyler Zemla and Ryan McMurray and Hongbin Chen and Arti Hurria and Hyman Muss and Cohen, {Harvey J.} and Rogerio Lilenbaum and Aminah Jatoi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jgo.2018.05.006",
language = "English (US)",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)

AU - Feliciano, Josephine L.

AU - Le-Rademacher, Jennifer

AU - Gajra, Ajeet

AU - Edelman, Martin J.

AU - Zemla, Tyler

AU - McMurray, Ryan

AU - Chen, Hongbin

AU - Hurria, Arti

AU - Muss, Hyman

AU - Cohen, Harvey J.

AU - Lilenbaum, Rogerio

AU - Jatoi, Aminah

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: This study sought to define the role of first-line platinum-based doublet chemotherapy in older patients with non-small cell lung cancer (NSCLC). Materials and Methods: We analyzed three first-line NSCLC trials: CALGB 9730, CALGB 30203, and CALGB 30801, which tested carboplatin and paclitaxel; carboplatin and gemcitabine; and carboplatin with either pemetrexed or gemcitabine, respectively. Overall survival was the primary endpoint. Age-based comparisons with a cutpoint of 65 years were performed with Cox proportional hazards models with adjustments for sex, tumor histology, cancer stage, chemotherapy, and smoking history and after stratifying by performance score. Secondary endpoints were grade 3–5 adverse events, chemotherapy cycles completed, and whether toxicity prompted chemotherapy discontinuation. Results: 730 patients were included; 337 (46%) were 65+ years of age. No statistically significant difference in survival was observed for older (≥65) versus younger patients (HR = 1.096; 95% CI = (0.94, 1.28); p = 0.25). A trend emerged with increased odds of a grade 3–5 adverse event for patients ≥65 years versus <65 years (OR = 1.52; 95% CI = (0.99, 2.31); p = 0.05). The proportion of completed chemotherapy cycles was marginally lower in older patients (difference = −5%; 95% CI = (−9, 0.2); p = 0.06) for those ≥65 years versus <65 years, but no statistically significant difference occurred in the rate of chemotherapy discontinuation for toxicity (OR = 1.4; 95% CI = (0.85, 2.19); p = 0.21) for patients ≥65 years versus <65 years. A cutpoint of 70 years yielded similar results. Conclusion: These findings support carboplatin doublet-based chemotherapy in select older patients with advanced NSCLC.

AB - Objective: This study sought to define the role of first-line platinum-based doublet chemotherapy in older patients with non-small cell lung cancer (NSCLC). Materials and Methods: We analyzed three first-line NSCLC trials: CALGB 9730, CALGB 30203, and CALGB 30801, which tested carboplatin and paclitaxel; carboplatin and gemcitabine; and carboplatin with either pemetrexed or gemcitabine, respectively. Overall survival was the primary endpoint. Age-based comparisons with a cutpoint of 65 years were performed with Cox proportional hazards models with adjustments for sex, tumor histology, cancer stage, chemotherapy, and smoking history and after stratifying by performance score. Secondary endpoints were grade 3–5 adverse events, chemotherapy cycles completed, and whether toxicity prompted chemotherapy discontinuation. Results: 730 patients were included; 337 (46%) were 65+ years of age. No statistically significant difference in survival was observed for older (≥65) versus younger patients (HR = 1.096; 95% CI = (0.94, 1.28); p = 0.25). A trend emerged with increased odds of a grade 3–5 adverse event for patients ≥65 years versus <65 years (OR = 1.52; 95% CI = (0.99, 2.31); p = 0.05). The proportion of completed chemotherapy cycles was marginally lower in older patients (difference = −5%; 95% CI = (−9, 0.2); p = 0.06) for those ≥65 years versus <65 years, but no statistically significant difference occurred in the rate of chemotherapy discontinuation for toxicity (OR = 1.4; 95% CI = (0.85, 2.19); p = 0.21) for patients ≥65 years versus <65 years. A cutpoint of 70 years yielded similar results. Conclusion: These findings support carboplatin doublet-based chemotherapy in select older patients with advanced NSCLC.

KW - Carboplatin

KW - Chemotherapy

KW - Geriatric oncology

KW - Lung cancer

KW - Older patients

UR - http://www.scopus.com/inward/record.url?scp=85047405258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047405258&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2018.05.006

DO - 10.1016/j.jgo.2018.05.006

M3 - Article

C2 - 29848457

AN - SCOPUS:85047405258

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

ER -